Loading...
NPI 1154811917 · North Hollywood, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Gmi Laboratories LLC is a clinical medical laboratory provider located in North Hollywood, California. This profile covers 44 Medicare and 30 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Gmi Laboratories LLC |
| Address | 12840 Riverside Dr Ste 200 |
| City | North Hollywood |
| State | CA |
| ZIP | 91607 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 16, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $11.9M |
| Medicaid | $96K |
GMI LABORATORIES LLC’s code mix points to a clinical reference laboratory with heavy emphasis on nucleic acid amplified probe testing and definitive drug identification. The highest Medicare revenue codes are 87798 ($3.1M, 26.5%), G0483 ($1.7M, 14.8%) and 87150 ($1.5M, 13.0%), reflecting high-volume infectious agent NAAT work alongside substantial definitive drug-testing capability that typically requires GC/MS or LC/MS methods. Numerous other NAAT respiratory and STI codes appear in the top list, which aligns with a service line focused on molecular diagnostics and drug confirmation services.
Revenue concentration on Medicare is pronounced: the precomputed top three Medicare codes account for 54.3% of this provider’s total Medicare revenue. Those top three — 87798, G0483 and 87150 — together generate a majority of the $11.9M in Medicare revenue, indicating that a relatively small set of high-volume molecular and definitive drug tests drive most of the provider’s Medicare billing. This profile suggests operational dependence on those core testing lines.
Medicaid revenue is small in absolute scale relative to Medicare: the provider reports $96K in total Medicaid revenue versus $11.9M in Medicare revenue, indicating Medicare is the dominant payer. Medicaid billing is nonetheless concentrated as well — the precomputed top three Medicaid codes account for 58.2% of Medicaid revenue — with 87798 ($28.8K, 29.3%), G0483 ($18.4K, 18.7%) and 87640 ($10K, 10.2%) together forming the bulk of the $96K Medicaid footprint.
On Medicare this lab ranks as a major national player for several NAAT and definitive-testing codes. For example, 87798 ranks #18 of 1319 providers nationally (99th percentile; notably above typical national volume), G0483 ranks #12 of 1063 (99th percentile; notably above typical national volume), and 87150 ranks #9 of 190 (96th percentile; notably above typical national volume), which together indicate unusually high national volume for these specific services. These high national percentiles imply the lab is a significant supplier of selected molecular and drug-confirmation tests to the Medicare population.
State-level competitive positioning on Medicaid is more mixed but shows pockets of strength for specific assays. 87798 is at the 87th percentile in-state (#52 of 395; typical, unremarkable volume), G0483 sits at the 68th percentile in-state (#32 of 99; typical), while 87640 is more prominent at the 91st percentile in-state (#9 of 95; typical), and 87541 ranks #2 of 55 in-state (98th percentile; notably above typical state volume) despite contributing a smaller dollar amount to Medicaid revenue. This suggests the lab has selective advantages for particular organism-specific NAATs within California even though overall Medicaid revenue remains small.
Several individual Medicare codes are flagged as unusually high relative to national peers, creating multiple statistical outliers in the lab’s profile. Codes such as 87481, 87502, 87634, 87529 and 87426 are described as “extreme outlier” or “notably above typical national volume,” indicating exceptionally large Medicare claim volumes for certain respiratory and sexually transmitted infection NAATs and for multiplex influenza/respiratory panels. The presence of multiple extreme outliers implies concentrated scale in specific high-demand molecular assays rather than an evenly distributed testing mix.
Operational tenure and capability signals are consistent with a focused, modern molecular lab: the NPI was enumerated 2018-05-16 (~8 years ago), and the billing mix includes both high-throughput SARS-CoV-2 testing (U0004 appears on Medicare with 3.9K claims and $285.5K revenue) and advanced definitive drug testing (G0483). The combination of relatively recent enumeration, high national ranks on molecular codes, and presence of high-throughput COVID testing codes suggests an operational platform oriented toward high-volume molecular and confirmatory testing rather than low-acuity routine chemistry panels.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
44 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 91,640 | $30 | $3.1M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7,200 | $240 | $1.7M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 44,960 | $30 | $1.5M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 32,300 | $30 | $1.1M |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 7,520 | $90 | $706.9K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 7,520 | $70 | $518.7K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 15,080 | $30 | $512.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 4,860 | $60 | $296.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3,860 | $70 | $285.5K |
| 87498 | A lab tests a patient’s specimen to provide a definitive diagnosis of meningitis by amplified probe technique. | 7,570 | $30 | $257.2K |
Showing 1–10 of 44
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
44 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 5 | 70 | 360 | $240 | $427.9K |
| 87798 | 3 | 110 | 1,340 | $30 | $338.2K |
| 87150 | 1 | 30 | 1,690 | $30 | $222.6K |
| U0005 | 29 | 150 | 780 | $20 | $75.1K |
| U0004 | 3 | 40 | 410 | $70 | $73.6K |
| 87481 | 1 | 100 | 270 | $30 | $72.7K |
| 80307 | 8 | 150 | 220 | $60 | $69.2K |
| 87498 | 1 | 10 | 960 | $30 | $54.7K |
| 87634 | 2 | 40 | 50 | $70 | $53.2K |
| 86003 | 18 | 40 | 2,880 | $10 | $41.5K |
Showing 1–10 of 44
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
30 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3,610 | $10 | $28.8K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,060 | $10 | $18.4K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 3,350 | $1 | $10K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,700 | $1 | $5.4K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 2,600 | $1 | $5.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,560 | $1 | $4.7K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 3,360 | $1 | $3.4K |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 3,180 | $1 | $3.2K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 3,170 | $1 | $3.2K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 3,120 | $1 | $3.1K |
Showing 1–10 of 30
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
30 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 32 | 100 | 520 | $120 | $2.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 80 | 150 | 580 | $60 | $608.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 324 | 660 | 1,490 | $30 | $417.2K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 252 | 290 | 220 | $210 | $268.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 283 | 520 | 470 | $10 | $116K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 74 | 120 | 250 | $10 | $103.1K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 56 | 470 | 350 | $40 | $76.1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 99 | 310 | 270 | $30 | $70.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 52 | 400 | 330 | $20 | $67.9K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 9 | 150 | 180 | $40 | $65.2K |
Showing 1–10 of 30
Other providers in the same ZIP code as Gmi Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Sean Wollaston | CA | Specialist | $2.1M | $0 |
| Wonil Lee | CA | Specialist | $1.5M | $40 |
| Lori Birndorf | CA | Ophthalmology Physician | $664.2K | $541.2K |
| Mina Sarbaz | CA | Podiatrist | $220.9K | $0 |
| Western Pacific Med-corp | CA | Methadone Clinic | $158.3K | $50.3K |
| Amanda Barrinuevo | CA | Family Nurse Practitioner | $191K | $0 |
| Yoav Nagar | CA | Sports Physician Chiropractor | $154.9K | $0 |
| Hambartsoum Mekharian | CA | Acute Care Nurse Practitioner | $23.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.